Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2020.106879 http://scihub22266oqcxt.onion/10.1016/j.intimp.2020.106879 32795898!7414302!32795898     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2020 ; 88 (ä): 106879 Nephropedia Template TP {{tp|p=32795898|t=2020. Oxygen-ozone (O(2)-O(3)) immunoceutical therapy for patients with COVID-19 Preliminary evidence reported |pdf=|usr=}}{{32795898}} gab.com Text Oxygen-ozone (O(2)-O(3)) immunoceutical therapy for patients with COVID-19 Preliminary evidence reported JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32795898 #FOAvip OBJECTIVE: This study evaluated the potential efficacy of a novel approach to treat COVID-19 patients, using an oxygen-ozone (O(2)-O(3)) mixture, via a process called Oxygen-Ozone- Immunoceutical Therapy. The methodology met the criteria of a novel, promising approach to treat successfully elderly COVID-19 patients, particularly when hospitalized in intensive care units (ICUs) Experimental design: We investigated the therapeutic effect of 4 cycles of O(2)-O(3) in 50 hospitalized COVID-19 subjects suffering from acute respiratory disease syndrome (ARDS), aged more than 60 years, all males and undergoing non invasive mechanical ventilation in ICUs. RESULTS: Following O(2)-O(3) treatment a significant improvement in inflammation and oxygenation indexes occurred rapidly and within the first 9 days after the treatment, despite the expected 14-20 days. A significant reduction of inflammatory and thromboembolic markers (CRP, IL-6, D-dimer) was observed. Furthermore, amelioration in the major respiratory indexes, such as respiratory and gas exchange markers (SatO(2)%, PaO(2)/FiO(2) ratio), was reported. CONCLUSION: Our results show that O(2)-O(3) treatment would be a promising therapy for COVID-19 patients. It leads patients to a fast recovery from ARDS via the improvement of major respiratory indexes and blood gas parameters, following a relatively short time of dispensed forced ventilation (about one to two weeks). This study may encourage the scientific community to further investigate and evaluate the proposed method for the treatment of COVID-19 patients. Twit Text FOAVip Oxygen-ozone (O(2)-O(3)) immunoceutical therapy for patients with COVID-19 Preliminary evidence reported ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32795898 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32795898 #FOAvip English Wikipedia <ref>{{Cite pmid|32795898}}</ref> Oxygen-ozone (O(2)-O(3)) immunoceutical therapy for patients with COVID-19 Preliminary evidence reported #MMPMID32795898 Franzini M; Valdenassi L; Ricevuti G; Chirumbolo S; Depfenhart M; Bertossi D; Tirelli U Int Immunopharmacol 2020[Nov]; 88 (ä): 106879 PMID32795898show ga OBJECTIVE: This study evaluated the potential efficacy of a novel approach to treat COVID-19 patients, using an oxygen-ozone (O(2)-O(3)) mixture, via a process called Oxygen-Ozone- Immunoceutical Therapy. The methodology met the criteria of a novel, promising approach to treat successfully elderly COVID-19 patients, particularly when hospitalized in intensive care units (ICUs) Experimental design: We investigated the therapeutic effect of 4 cycles of O(2)-O(3) in 50 hospitalized COVID-19 subjects suffering from acute respiratory disease syndrome (ARDS), aged more than 60 years, all males and undergoing non invasive mechanical ventilation in ICUs. RESULTS: Following O(2)-O(3) treatment a significant improvement in inflammation and oxygenation indexes occurred rapidly and within the first 9 days after the treatment, despite the expected 14-20 days. A significant reduction of inflammatory and thromboembolic markers (CRP, IL-6, D-dimer) was observed. Furthermore, amelioration in the major respiratory indexes, such as respiratory and gas exchange markers (SatO(2)%, PaO(2)/FiO(2) ratio), was reported. CONCLUSION: Our results show that O(2)-O(3) treatment would be a promising therapy for COVID-19 patients. It leads patients to a fast recovery from ARDS via the improvement of major respiratory indexes and blood gas parameters, following a relatively short time of dispensed forced ventilation (about one to two weeks). This study may encourage the scientific community to further investigate and evaluate the proposed method for the treatment of COVID-19 patients. |Aged[MESH] |Betacoronavirus[MESH] |Blood Gas Analysis[MESH] |COVID-19[MESH] |Coronavirus Infections/immunology/*therapy[MESH] |Humans[MESH] |Immunotherapy/instrumentation/*methods[MESH] |Infusions, Intravenous[MESH] |Intensive Care Units[MESH] |Oxygen/administration & dosage/*therapeutic use[MESH] |Ozone/administration & dosage/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/immunology/*therapy[MESH] |Respiration, Artificial[MESH] |Respiratory Distress Syndrome/immunology/*therapy[MESH] |SARS-CoV-2[MESH]Oxygen-ozone (O(2)-O(3)) immunoceutical therapy for patients with COVI(epmc).pdf DeepDyve Pubget Overpricing